India's Excellent Standing in Biotechnology Industry Drives Rapid Growth Opportunities
Frost & Sullivan Transformational Health Team discusses government incentives and investments leading the transition to bio-economy
MOUNTAIN VIEW, California, June 2, 2016 /PRNewswire/ -- Currently, India is amongst the top 12 biotechnology destinations in the world and ranks third in the Asia-Pacific region. Despite the economic downturn in 2013 to 2014, the industry has experienced rapid growth due to increasing foreign investments, supportive government policies, increasing exports and a skilled workforce. India's biotechnology industry is in a great position to transition to bio-economy. This will allow India to re-establish cornerstones defining the competitiveness of existing sectors, providing them with a favorable setting to operate and grow.
Logo - http://photos.prnewswire.com/prnh/20160601/374425LOGO
A recent white paper from Frost & Sullivan, India Ripe for Biotech Industry Growth, finds a fertile ecosystem will enable India to enter the biologics market, which is expected to reach $314.8 billion at a compound annual growth rate (CAGR) of 8.4 percent. India is a global leader in the world generics market, and with its strong positioning to provide affordable healthcare, biosimilars will be a perfect fit for Indian companies.
Click here to download the white paper, or visit: http://frost.ly/fg.
The country has the essential ingredients for success, including:
- Top-ranked universities discovering and developing new technologies
- The formation of new companies
- The expansion of established companies
- Introduction of new products in the market
- A capable workforce
- An improving quality of life
"India has world-class strengths in chemical, biological and environmental sciences alongside a remarkable process engineering community. These equip the Indian research community to provide the foundation, understanding and breakthroughs to advance large-scale opportunities," said Frost & Sullivan Partner and Transformational Health Senior Vice President Reenita Das. "The industry is expected to witness a growth rate of over 20 percent in the biotechnology sector and presents lucrative investment opportunities for global companies."
The creation of competitive products and services as well as legislation will direct the paradigm shift from biotechnology to bio-economy. It is vital that new policy actions support the growth of a sustainable bio-economy.
Furthermore, it is essential to address the critical issues:
- Establish a simplified and efficient business process to encourage large-scale foreign direct investment.
- Re-evaluate biodiversity laws seriously impacting entrepreneurial efforts to create new industries and jobs locally.
"Indian biotechnology expertise promotes the creation of new businesses from pharmaceutical research, medical technology, healthcare IT and healthcare service innovations," noted Das. "In addition, India's excellent clinical trials and manufacturing infrastructure, as well as its position with Trade-Related Aspects of Intellectual Property Rights (TRIPS), provided the industry an opportunity to thrive."
Das will participate in the upcoming Confederation of Indian Industry (CII) event at BIO 2016 as a presenter for the Inauguration of Indian Pavilion. To view more information about the event, please visit http://frost.ly/f6. The Inauguration of Indian Pavilion will be held at the Moscone Center, on June 7, 2016 at 12:00 p.m. PT.
About Confederation of Indian Industry
The Confederation of Indian Industry (CII) works to create and sustain an environment conducive to the development of India, partnering industry, Government, and civil society, through advisory and consultative processes.
CII is a non-government, not-for-profit, industry-led and industry-managed organization, playing a proactive role in India's development process. Founded in 1895, India's premier business association has around 8000 members, from the private as well as public sectors, including SMEs and MNCs, and an indirect membership of over 200,000 enterprises from around 240 national and regional sectoral industry bodies.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact:
Kayla Belcher
Corporate Communications
P: 210.247.2450
E: kayla.belcher@frost.com
Share this article